Amgen executives detailed their alleged Aranesp "overfill" kickback scheme in a set of PowerPoint slides and Excel spreadsheets, according to a lawsuit filed by the New York State Attorney General.

Amgen Inc.’s anemia treatment Aranesp is safe for use in kidney patients whose disease doesn’t require dialysis, a U.S. panel found. Outside advisors to the Food and Drug Administration said the ...

Amgen is the subject of the FDA’s latest untitled letters. The regulator’s Office of Prescription Drug Promotion (OPDP) knocked the company for a mailer promoting it its chronic kidney disease anemia ...

LOS ANGELES, Aug 25 (Reuters) - A trial of Amgen Inc's Aranesp found the blockbuster anemia drug does not have a significant effect on the risk of heart attack and other cardiac events in kidney ...

NEW YORK, Feb 16 (Reuters) - Amgen Inc.'s multibillion-dollar anemia drug Aranesp is facing further safety concerns after a medical newsletter reported on Friday that a Danish study of the drug in ...

THOUSAND OAKS, Calif., September 7, 2006 -- Amgen (NASDAQ: AMGN) today announced the launch of the Aranesp® (darbepoetin alfa) prefilled SureClick TM autoinjector for patients with ...

Please provide your email address to receive an email when new articles are posted on . Aranesp use has increased from 2.5% in January 2014 to 21% in December 2015, while epoetin alfa use has fallen ...

Amgen has dodged a potential Aranesp bullet. A new study dubbed "TREAT" showed that while the anemia drug didn't improve the heart health of patients with chronic kidney disease, it didn't hurt, ...

Biotechnology giant Amgen today pleaded guilty in federal court to a misdemeanor charge of misbranding Aranesp (darbepoetin alfa), its highly successful anemia drug. The government accused Amgen of ...

Amgen, Inc. AMGN announced positive data on Aranesp from the randomized, double-blind, placebo-controlled phase III ARCADE study. The company said that Aranesp met the primary endpoint of reducing the ...